CTSL and prostate cancer: In prostate cancer, the different CUX1 variants even seem to mediate antagonistic effects depending on cathepsin L activity: In androgen-sensitive tumors, cathepsin L is highly expressed and cleaves CUX1 into the tumor-promoting p110 isoform.